Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.

Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS.

J Gastrointest Cancer. 2013 Jun;44(2):182-9. doi: 10.1007/s12029-012-9466-2.

PMID:
23208490
3.

Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.

Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.

Anticancer Drugs. 2007 Mar;18(3):263-71.

PMID:
17264757
4.

Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.

Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW.

Oncologist. 2001;6(6):488-95.

5.

Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.

Araneo M, Bruckner HW, Grossbard ML, Frager D, Homel P, Marino J, DeGregorio P, Mortazabi F, Firoozi K, Jindal K, Kozuch P.

Cancer Invest. 2003;21(4):489-96.

PMID:
14533437
6.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.

Invest New Drugs. 2005 Aug;23(4):369-75. Erratum in: Invest New Drugs. 2005 Dec;23(6):603. Kopteridis, Petros [corrected to Kopterides, Petros].

PMID:
16012797
7.
8.

Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.

Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM.

J Clin Oncol. 2003 Oct 15;21(20):3761-9. Epub 2003 Sep 8.

PMID:
12963697
9.

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.

Assaf E, Verlinde-Carvalho M, Delbaldo C, Grenier J, Sellam Z, Pouessel D, Bouaita L, Baumgaertner I, Sobhani I, Tayar C, Paul M, Culine S.

Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.

PMID:
21778770
10.

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.

Lee MG, Lee SH, Lee SJ, Lee YS, Hwang JH, Ryu JK, Kim YT, Kim DU, Woo SM.

Chemotherapy. 2013;59(4):273-9. doi: 10.1159/000356158. Epub 2014 Jan 18.

PMID:
24457620
11.

Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract.

Gkioulbasanis I, Souglakos J, Vardakis N, Kotsakis A, Saridaki Z, Kentepozidis N, Polyzos A, Giassas S, Ignatiadis M, Bozionelou V, Christophylakis C, Georgoulias V.

J BUON. 2007 Apr-Jun;12(2):197-202.

PMID:
17600872
12.

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group..

Lancet. 2016 Feb 6;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536.

PMID:
26615328
13.

A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.

Chiesa MD, Buti S, Tomasello G, Negri F, Buononato M, Brunelli A, Lazzarelli S, Brighenti M, Donati G, Passalacqua R.

Tumori. 2007 May-Jun;93(3):244-7.

14.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer.; PRODIGE Intergroup..

N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.

15.
16.

Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.

Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT.

J Gastroenterol Hepatol. 2006 May;21(5):874-9.

PMID:
16704539
17.

Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.

Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.

Jpn J Clin Oncol. 2007 Sep;37(9):686-91. Epub 2007 Aug 24.

PMID:
17720736
18.

FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.

Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P.

World J Gastroenterol. 2012 Sep 7;18(33):4533-41. doi: 10.3748/wjg.v18.i33.4533.

19.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T.

J Clin Oncol. 2013 Jan 1;31(1):23-9. doi: 10.1200/JCO.2012.44.4869. Epub 2012 Dec 3.

PMID:
23213101
20.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.

Kuo T, Cho CD, Halsey J, Wakelee HA, Advani RH, Ford JM, Fisher GA, Sikic BI.

J Clin Oncol. 2005 Aug 20;23(24):5613-9.

PMID:
16110021

Supplemental Content

Support Center